GIP and polycystic ovary syndrome: It is also likely that glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists will play a greater role in the management of PCOS as these medications become ever more widely used for weight loss and the management of metabolic syndrome and diabetes.